AstraZeneca PLC

Discover how AstraZeneca’s recent FDA approval of Imfinzi for bladder cancer and targeted anselamimab results reshape its oncology strategy and market outlook.

Explore how AstraZeneca’s May 2026 FDA approvals of BAXFENDY™ and Enhertu shape its market and oncology pipeline—and why shares slipped.

Discover AstraZeneca’s AI partnership with Owkin, breakthrough hypoparathyroidism drug results, and recent patent moves – all shaping the future of pharma.

Discover why Deutsche Bank upgraded AstraZeneca’s target to 11,500 GBp: a strong oncology pipeline, solid balance sheet and steady growth outlook make AZN a top pharma pick for investors.

Discover how AstraZeneca’s new U.S. biopharma leadership and Nasdaq‑100 exit sharpen growth focus and boost shareholder value.

Explore AstraZeneca’s latest oncology news: LATIFY setback, BTD for ENHERTU, and a KRAS partnership—what this means for investors and the future of cancer therapy.

Explore how AstraZeneca’s EU Saphnelo approval and U.S. Enhertu launch drive growth—while a pending vaccine lawsuit adds new risk to investor outlook.

Read how AstraZeneca beat Q3 earnings expectations, driven by oncology & cardiovascular sales, with a strong pipeline and U.S. pricing deal boosting confidence for 2026.

AstraZeneca PLC has reached a pricing agreement with the US administration to offer discounted medications to American patients, while also expanding its investment in a new manufacturing facility in Virginia, valued at $4.5 billion.

AstraZeneca PLC reports a 11.7% surge in revenue to $14.457 billion in Q2 2025, driven by strategic collaborations and regulatory milestones in its oncology, cardiovascular, and respiratory therapeutic areas.